Bausch + Lomb has announced it has completed its $500 million acquisition of ISTA Pharmaceuticals, according to a news release.
Bausch + Lomb announced the acquisition of ISTA in March.
ISTA is one of the largest branded prescription eye care businesses in the United States and features an emerging allergy drug franchise. It currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis.
"This combination is a big step for Bausch + Lomb and an exciting development for eye health," said Brent Saunders, president and CEO of Bausch + Lomb, in the release. "Together, we are building a high-performance company that can deliver even more benefits for the patients and customers we serve. ISTA's business complements our own very well, and we are excited about the opportunities this transaction creates."
Related Articles on Company Acquisitions:
Siegfried Holding Acquires Alliance Medical Products
Mindray Medical to Acquire Controlling Stake in Dragonbio
ConvaTec Acquires Trio Healthcare International